L. Dousset

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study

Marie Kostine, L. Rouxel, Thomas Barnetche et al. · Annals of the Rheumatic Diseases · 2017 · 302 citations

Life Sciences, Immunology, Oncology +17

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo

M. Larsabal, A. Marti, C. Jacquemin et al. · Journal of the American Academy of Dermatology · 2017 · 157 citations

Life Sciences, Immunology, Pathology +9

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Guillaume Manson, Alexandre Maria, F. Poizeau et al. · Journal for ImmunoTherapy of Cancer · 2019 · 106 citations · Full text

Life Sciences, Immunology, Oncology +17

Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

Marie Kostine, Eleonora Mauric, Alice Tison et al. · European Journal of Cancer · 2021 · 93 citations · Full text

Medicine, Oncology, Pharmacology +15

Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on polymerase chain reaction and serology testing*

Laurence Le Cleach, L. Dousset, H. Assier et al. · British Journal of Dermatology · 2020 · 80 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14